Abstract
Summary: BLU-667 is a next-generation RET inhibitor that maximizes on-target and minimizes off-target effects. It is an exemplar of genotype-driven drug development followed by multi-histology basket trial validation that is becoming a paradigm for precision oncology. Cancer Discov; 8(7); 797–9. ©2018 AACR.
See related article by Subbiah et al., p. 836.
- ©2018 American Association for Cancer Research.
July 2018
Volume 8, Issue 7
Volume 8, Issue 7
Stop fRETting the Target: Next-Generation RET Inhibitors Have Arrived
Jump to section
Advertisement